MARS: mutation-adjusted risk score for advanced systemic mastocytosis

1 Vues
administrator
administrator
07/09/23

Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

  • Catégorie

Montre plus

Aucun commentaire trouvé

Commentaires de Facebook

Suivant